Medical device company SeaStar Medical reported a fourfold increase in first-quarter sales for QUELIMMUNE, its FDA-approved treatment for pediatric acute kidney injury (AKI), signaling potential market expansion and strategic growth.
The company's QUELIMMUNE product, currently approved for pediatric patients with AKI due to sepsis, saw net product revenue increase to $293,000 in the first quarter of 2025, compared to $67,500 in the previous quarter. This growth reflects increasing adoption among pediatric healthcare providers and demonstrates the therapy's potential clinical value.
SeaStar is now targeting the significantly larger adult AKI market, which represents an estimated $4.5 billion annual opportunity. The company's NEUTRALIZE-AKI pivotal trial, focused on adult patients, has reached 50% enrollment and is expected to support a potential FDA approval in 2026.
CEO Eric Schlorff emphasized the company's commitment to expanding its therapeutic reach, noting that QUELIMMUNE offers organ-sparing and potentially life-saving outcomes for critically ill patients. The therapy's ability to integrate with existing hospital workflows provides a strategic advantage in market penetration.
The company's financial performance also showed improvement, with net losses narrowing to $3.8 million in the first quarter, compared to $12.7 million in the same period last year. SeaStar concluded the quarter with $5.3 million in cash, supported by a $6 million registered direct offering.
As SeaStar continues to advance its Selective Cytopheretic Device (SCD) therapy, the company is positioning itself as an innovative player in treating critical care patients with organ failure risks, with particular focus on expanding treatment options for both pediatric and adult populations.
